Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4

被引:35
|
作者
Regev-Shoshani, G
Shoseyov, O
Kerem, Z
机构
[1] Hebrew Univ Jerusalem, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel
[2] Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Robert H Smith Inst Plant Sci & Genet Agr, IL-76100 Rehovot, Israel
关键词
resveratrol; CYP3A4; piceid; kinetics; cyclosporine; polyphenols;
D O I
10.1016/j.bbrc.2004.08.141
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Resveratrol, a polyphenol found in red wine, was recently suggested to act as an irreversible, mechanism-based inactivator of cytochrome P450 3A4 (CYP3A4). We found a significant inhibition of human CYP3A4-dependent transformation of cyclosporine by resveratrol, with IC50 = 4.5 muM. We studied the kinetics parameters of CYP3A4 transformation of resveratrol and structurally related, naturally occurring stilbenes. Resveratrol, piceid, resveratroloside, 5,4'-dihydroxy-3-O-methoxystilbene, and 5,3-dihydroxy-4'-O-methoxystilbene were all shown to inhibit hydroxylation of testosterone by CYP3A4. Both methoxy-stilbenes had lower IC50 values, ranging from 0.43 to 0.47 muM, suggesting that lipophilicity rather than number or positions of free hydroxyls (3,5 or 5,4') determines the CYP3A4 inhibition capacity of polyphenols. In line with these findings, both glucosyl-stilbenes were found to be weak inhibitors of CYP3A4. The affinity of the enzyme towards methoxy-stilbenes, expressed as apparent K-m, was indeed higher than those for the parent resveratrol and its glucosides, in CYP3A4 reaction mixtures. V-max values were similar, except for piceid. These results support the role of lipophilicity in the interaction of polyphenols with CYP3A4. It is suggested that selective structural modifications of substrates add significantly to knowledge acquired through molecular modifications of the enzyme. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:668 / 673
页数:6
相关论文
共 50 条
  • [21] Peripheral Ligand-binding Site in Cytochrome P450 3A4 Located with Fluorescence Resonance Energy Transfer (FRET)
    Davydov, Dmitri R.
    Rumfeldt, Jessica A. O.
    Sineva, Elena V.
    Fernando, Harshica
    Davydova, Nadezhda Y.
    Halpert, James R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (09) : 6797 - 6809
  • [22] Analysis of the Molecular Interactions between Cytochromes P450 3A4 and 1A2 and Aflatoxins: A Docking Study
    Abril Garcia-Montoya, Isui
    Rosario Flores-Holguin, Norma
    Landeros-Martinez, Linda-Lucila
    Alvarado-Gonzalez, Monica
    Rascon-Cruz, Quintin
    Elena Fuentes-Montero, Maria
    Palomares-Baez, Pedro
    Maria Rodriguez-Valdez, Luz
    APPLIED SCIENCES-BASEL, 2019, 9 (12):
  • [23] Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5
    Tang, Lloyd Wei Tat
    Verma, Ravi Kumar
    Yong, Ren Ping
    Li, Xin
    Wang, Lili
    Lin, Qingsong
    Fan, Hao
    Chan, Eric Chun Yong
    MOLECULAR PHARMACOLOGY, 2021, 100 (03) : 224 - 236
  • [24] Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful
    Fernando González
    Ricardo Valjalo
    World Journal of Transplantation, 2015, (04) : 338 - 347
  • [25] Cytochrome P450 3A4*1B as Pharmacogenomic Predictor of Tacrolimus Pharmacokinetics and Clinical Outcome in the Liver Transplant Recipients
    Albekairy, Abdulkareem
    Alkatheri, Abdulmalik
    Fujita, Shiro
    Hemming, Alan
    Howard, Richard
    Reed, Alan
    Karlix, Janet
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2013, 19 (02) : 89 - 95
  • [26] Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin
    Ling, Spencer Y.
    Huizinga, Robert B.
    Mayo, Patrick R.
    Larouche, Richard
    Freitag, Derrick G.
    Aspeslet, Launa J.
    Foster, Robert T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 1039 - 1050
  • [27] Management of Metabolic Cytochrome P450 3A4 Drug-Drug Interaction between Everolimus and Azole Antifungals in a Renal Transplant Patient
    Billaud, E. M.
    Antoine, C.
    Berge, M.
    Abboud, I.
    Lefeuvre, S.
    Benammar, M.
    Glotz, D.
    CLINICAL DRUG INVESTIGATION, 2009, 29 (07) : 481 - 486
  • [28] Cytochrome P450 3A polymorphisms and immunosuppressive drugs
    Thervet, E
    Legendre, C
    Beaune, P
    Anglicheau, D
    PHARMACOGENOMICS, 2005, 6 (01) : 37 - 47
  • [29] Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin
    Hong, Soon-Pyo
    Yang, Joon-Seung
    Han, Jung-Yeon
    Ha, Sung-Il
    Chung, Joong-Wha
    Koh, Young-Youp
    Chang, Kyong-Sig
    Choi, Dong-Hyun
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (01) : 129 - 135
  • [30] Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics
    Koley, AP
    Robinson, RC
    Friedman, FK
    BIOCHIMIE, 1996, 78 (8-9) : 706 - 713